HCW Biologics is trading at $2.66 (6.4% up) in pre-market, bouncing after a steep multi-day selloff from above $4 to $2.50.
- The move follows recent volatility surrounding the company’s July 23 announcement requesting a Type B pre-IND FDA meeting for its lead candidate, HCW11-018b.
- Today’s gain also comes amid a broader risk-on backdrop with major indices trading higher.